Since the pathogenesis of HND involves T cell subsets expressing OX40, therapies targeting OX40/40L (i.e., rocatinlimab and amlitelimab) are logical options that act via modulation of effector T cell survival and expansion [138]. This evidence concerns the gene TNFRSF4 and tooth and nail syndrome.